New hope for Tough-to-Treat colorectal cancer: experimental combo enters Late-Stage trial
NCT ID NCT07361003
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding the experimental drug suvemcitug to standard chemotherapy (trifluridine/tipiracil) helps people with metastatic colorectal cancer that no longer responds to other treatments live longer. About 464 participants will receive either the combination or a placebo plus chemo. The study first checks safety, then measures overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
suvemcitug (an anti-VEGF drug) plus trifluridine/tipiracil chemotherapy tablets
What this could lead to
If it works, this combination could offer a new treatment option that helps people with advanced colorectal cancer live longer after other treatments have failed.
What could go wrong
This is still being tested, and the added benefit of suvemcitug is unproven. Side effects from the combination could be worse than chemo alone, and the trial may not show a survival improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, Fujian, 350014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Harbin Medical University University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The First Affiliated Hospital of Nanjing Medical University
RECRUITINGNanjing, Jiangsu, 210029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, 310009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Tianjin Medical University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact